

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Neurotech Co., Ltd.	09/25/2009
RECEIVING PARTY DATA	
Name:	Neurotech Pharmaceuticals Co., Ltd.
Street Address:	Neurotech Pharmaceuticals Research Institute
Internal Address:	Ajou University San5, Wonchun-dong, Youngton-gu
City:	Suwon, Gyeonggi
State/Country:	REPUBLIC OF KOREA
Postal Code:	443-749
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	11205313
CORRESPONDENCE DATA	
Fax Number:	(206)682-6031
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	2066224900
Email:	millicents@seedip.com
Correspondent Name:	Seed IP Law Group PLLC
Address Line 1:	701 Fifth Avenue
Address Line 2:	Suite 5400
Address Line 4:	Seattle, WASHINGTON 98104
ATTORNEY DOCKET NUMBER:	110200.402C3
NAME OF SUBMITTER:	Richard G. Sharkey, Ph.D.
Total Attachments: 2 source=Assignment#page1.tif source=Assignment#page2.tif	

CH \$40.00 11205313

501007879

PATENT
 REEL: 023478 FRAME: 0096

ASSIGNMENT

WHEREAS, Neurotech Co., Ltd. (hereinafter referred to as ASSIGNOR), a corporation having had its principal offices at 106, Industrial Academy, Ajou University, 29-9 Wonchun-dong, Paldal-ku, Suwon-si, Kyunggi-do 442-380, South Korea, is owner of an invention entitled "COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING NEURODEGENERATION IN ACUTE AND CHRONIC INJURIES IN THE CENTRAL NERVOUS SYSTEM," as described and claimed in United States Letters Patent No. 6,573,402 issued June 3, 2003, which United States Letters Patent matured from United States Application No. 10/206,772 filed July 29, 2002, which application is a continuation of United States Patent Application No. 09/557,001 filed April 20, 2000 and abandoned; as described and claimed in United States Letters Patent No. 6,964,982 issued November 15, 2005, which United States Letters Patent matured from continuation United States Patent Application No. 10/206,765 filed July 29, 2002; as described and claimed in continuation United States Patent Application No. 11/205,313 filed August 17, 2005, now pending; and in any and all divisions, reissues and continuations thereof and patents therefrom; and in any and all corresponding foreign applications derived from International Application No. PCT/KR00/00366 and patents therefrom;

WHEREAS, Neurotech Pharmaceuticals Co., Ltd. (hereinafter referred to as ASSIGNEE), a corporation having its principal offices at Neurotech Pharmaceuticals Research Institute, Ajou University San5, Wonchun-dong, Youngton-gu, Suwon, Gyeonggi 443-749, South Korea, is desirous of acquiring the entire right, title and interest in and to said application and said patents and in any and all divisions, reissues and continuations thereof and patents therefrom; and any and all corresponding foreign applications and patents therefrom;

NOW, THEREFORE, in exchange for good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR hereby sells, assigns and transfers unto said ASSIGNEE the entire right, title and interest in and to said invention, said application, said patents and any and all letters patent which may be granted for said invention in the United States of America and its territorial possessions including any extensions or adjustments in term thereof and in any and all foreign countries, and in any and all divisions, reissues and continuations thereof, including the right to file foreign applications directly in the name of

ASSIGNEE and to claim priority rights deriving from said United States application or said International application to which said foreign applications are entitled by virtue of international convention, treaty or otherwise, said invention, application and all letters patent on said invention to be held and enjoyed by ASSIGNEE and its successors and assigns for their use and benefit and of their successors and assigns as fully and entirely as the same would have been held and enjoyed by ASSIGNOR had this assignment, transfer and sale not been made. ASSIGNOR hereby authorizes and requests the Commissioner of Patents and Trademarks to issue all letters patent on said invention to ASSIGNEE. ASSIGNOR agrees to execute all instruments and documents required for the making and prosecution of applications for United States and foreign letters patent on said invention, for litigation regarding said letters patent, or for the purpose of protecting title to said invention or letters patent therefor.

NEUROTECH CO., LTD.

25 September, 2009

Date

Byoung Joo Gwag

Byoung Joo Gwag

I certify that I know or have satisfactory evidence that Byoung Joo Gwag signed this instrument as the President of Neurotech Co., Ltd. of his own free will, as a voluntary act for the uses and purposes mentioned in the instrument.

Date 9/25/2009
(Type or Print Date)

Signed at Seoul, South Korea

Young Ae Lee
(Type or Print Name of Witness)

[Signature]
(Signature of Witness)

MillicentS/1434274